Venetoclax (ABT-199, GDC-0199)

目录号:S8048

Venetoclax (ABT-199, GDC-0199) Chemical Structure

Molecular Weight(MW): 868.44

Venetoclax (ABT-199, GDC-0199)是一种Bcl-2选择性抑制剂,无细胞试验中Ki为<0.01 nM,比作用于Bcl-xL和Bcl-w选择性高4800倍以上,对Mcl-1没有抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 5561.46 现货
RMB 2196.04 现货
RMB 7942.49 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的3个实验数据:

  • THP-1 cells were treated with cytarabine alone and in combination with ABT-199 for 8 h. Whole cell lysates were extracted and subjected to Western blotting, and probed with anti-γH2AX or -β-actin antibody. Densitometry for γH2AX expression was measured, normalized to β-actin, and graphed as fold change compared to the no drug control. The data are presented as mean ± standard error from at least 3 independent Western blots. * indicates p < 0.05.

    Mol Oncol 2014 10.1016/j.molonc.2014.09.008. Venetoclax (ABT-199, GDC-0199) purchased from Selleck.

    C33A cells were treated with ABC294640 (5 μmol/L), together with/out ABT-737 (200 nM) or GDC-0199 (200 nM), cells were further cultured for indicated time, cell growth (MTT assay, (A) and apoptosis (Histone DNA ELISA assay, (B) were tested.

    Oncotarget, 2017, 9(2):2384-2394. Venetoclax (ABT-199, GDC-0199) purchased from Selleck.

  • CLL cells were incubated with drugs immediately or co-cultured on CD154 stroma overnight and incubated with the indicated concentrations of ABT-199.

    J Biol Chem 2014 289(23), 16190-9. Venetoclax (ABT-199, GDC-0199) purchased from Selleck.

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

产品描述 Venetoclax (ABT-199, GDC-0199)是一种Bcl-2选择性抑制剂,无细胞试验中Ki为<0.01 nM,比作用于Bcl-xL和Bcl-w选择性高4800倍以上,对Mcl-1没有抑制活性。Phase 3。
特性 ABT-263 (Navitoclax)的重组
靶点
Bcl-2 [1]
(Cell-free assay)
<0.01 nM(Ki)
体外研究

ABT-199 对Bcl-xL, Mcl-1 和Bcl-w具有低的敏感性,Ki分别为48 nM, >444 nM 和 245 nM。ABT-199 有效抑制FL5.12-Bcl-2 细胞, RS4;11细胞, EC50分别为4 nM 和 8 nM,作用于 FL5.12-Bcl-xL细胞具有低活性,EC50为261 nM。ABT-199 诱导RS4;11 细胞快速凋亡,细胞色素c释放,caspase激活,磷脂酰丝氨酸外化,及sub-G0/G1 DNA积累。定量免疫印迹表明,ABT-199对包括NHL,DLBCL,MCL,AML和ALL细胞系的灵敏度,与Bcl-2的表达强烈相关。ABT-199也诱导 CLL 凋亡,平均EC50 为3.0 nM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CS-THL1 MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm0NlAhdk1? NEDXSpA4OiCq NH7h[VJFVVOR MV;Jcohq[mm2czDj[YxtKGe{b4f0bEBie3Onc4Pl[EBjgSClZXzsJJZq[WKrbHn0fS=> NEP1dFEzPTlzNk[5PC=>
CS-THL1 MWnBdI9xfG:2aXOgRZN{[Xl? M4nIOVI2KG6P MYTEUXNQ NYPheXpxUW6mdXPld{BieG:ydH;zbZM> M{HvTFI2QTF4Nkm4
DoGKiT MojtRZBweHSxdHnjJGF{e2G7 M334bFUxKG6P NGXkWFhFVVOR MWXJcoR2[2W|IHHwc5B1d3Orcx?= MljYNlU6OTZ4OUi=
RS4-11 MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu5cZM5PzJiaB?= NYO0c4tFUUN3ME2wMlA1ODJizszN NF64eIIzPTZ2OUe2PC=>
NALM-6 M2\ne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LsNVczKGh? M4r4WWlEPTB-MzFOwG0> M4DSbVI2PjR7N{[4
SU-DHL-6 M1rjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfxVlhWOC56IN88US=> MWXJcohq[mm2czDj[YxtKGe{b4f0bEBie3Onc4Pl[EBjgSClZXzsJJZq[WKrbHn0fS=> MXmyOVU6ODhyMx?=
OCI-Ly19 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\5TGoyKM7:TR?= M4PZS2lvcGmkaYTzJINmdGxiZ4Lve5RpKGG|c3Xzd4VlKGK7IHPlcIwhfmmjYnnsbZR6 NVnpdoN{OjV3OUC4NFM>
SU-DHL-6 M2rUWWZ2dmO2aX;uJGF{e2G7 NFjoZZcxNjd3IN88US=> NEDC[WEyQCCq MknjTY5kemWjc3XzJJBzdy2|dYL2bZZidCCycn;0[YlvKE2FTD2xJIV5eHKnc4Ppc44> NIS4Rm4zPTV7MEiwNy=>
KCL22 NUXqdG57TnWwY4Tpc44hSXO|YYm= NFLN[5IzKM7:TR?= M1fzNFQ5KGh? NHLINFBFVVOR Ml7UTY5kemWjc3XzJGRPSSCocnHnZY1mdnSjdHnvci=> M4r4WFI2OzN|MkWy
LOUCY NIjLVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEe5eYEyOCEQvF2= Ml;HOFghcA>? NFnlZpBFVVOR NVHTWFJ2UUN3ME2wMlAyOzlizszN M4POZ|I2OzBzN{C0
ALL-SIL Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTB[ZpjOTBizszN M1fDcVQ5KGh? NUG5XoFXTE2VTx?= NIG4eI9KSzVyPUCuNVgxOyEQvF2= Mnq2NlU{ODF5MES=
CUTLL1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjwV3gyOCEQvF2= MlXROFghcA>? M4W5SGROW09? MnPKTWM2OD1yLkO4NlMh|ryP M4nJcVI2OzBzN{C0
KOPTK1 MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvJfGcyOCEQvF2= Ml7EOFghcA>? M1nFWGROW09? NXXYbnpsUUN3ME2wMlY1OzJizszN NXiySmtCOjV|MEG3NFQ>
DND-41 M1LQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz3PFZYOTBizszN MnTaOFghcA>? NVfCfZJ7TE2VTx?= MVXJR|UxRTFwOU[5OUDPxE1? M17DR|I2OzBzN{C0
PF-382 NX3DWGZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfxNVAh|ryP NGO1Wpk1QCCq MojYSG1UVw>? MXnJR|UxRTJwMUiyOEDPxE1? M3rIVlI2OzBzN{C0
KARPAS-45 NU\WU2hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXyxNEDPxE1? MYm0PEBp NYjQUXR{TE2VTx?= MVLJR|UxRTNwMkKyOUDPxE1? NFu0S4MzPTNyMUewOC=>
PEER MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXZWoJTOTBizszN MVK0PEBp M1fOemROW09? NInQW5FKSzVyPUSuOlQxOyEQvF2= NGCyXmczPTNyMUewOC=>
CX-1 NIrZWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;PTWsyODBizszN NHjuVpk4OiCq M1fxfWlEPTB;Nj63JO69VQ>? NHX0[pAzPTJyOEi4Ni=>
LS147T M{DBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuxNFAh|ryP MYm3NkBp M4LBeGlEPTB;MkmuOUDPxE1? NIHtVJMzPTJyOEi4Ni=>
HL-60 NIrEellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[0PEBp MV\JR|UxRDFizszN MorGNlQ{PDZzMU[=
MOLM-13 NX;ieJpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[0PEBp MUTJR|UxRDFizszN NHfDOlMzPDN2NkGxOi=>
OCI-AML2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYC0PEBp MlyxTWM2ODxzIN88US=> MWSyOFM1PjFzNh?=
Kasumi-1 MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPTOFghcA>? MkDzTWM2ODxzIN88US=> MYiyOFM1PjFzNh?=
KG-1 M{fSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TncFQ5KGh? Mn:xTWM2ODxzIN88US=> NHX5WZgzPDN2NkGxOi=>
THP-1 NYiyTYl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWC0PEBp M2G3d2lEPTB:MTFOwG0> M2\uflI1OzR4MUG2
MOLM-14 M4THW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e3bVQ5KGh? M4XFemlEPTB:MTFOwG0> MVKyOFM1PjFzNh?=
MOLM-13 MnnjRZBweHSxdHnjJGF{e2G7 MVK1NEBvVQ>? NWfpWnlxOjRiaB?= NVfUfnRCSXCxcITvd4l{KGmwZIXjeIlwdg>? NEnNOm8zPDN2NkGxOi=>
HSB M{jaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXixNEDPxE1? MnrmOFghcA>? NEjUV2JFVVOR NUTPSHMzUUN3ME20MlQ1QCEQvF2= NWnE[|d{OjR|NEK5OFg>
MOLT4 NYf1XnJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGxNEDPxE1? NGThUmk1QCCq MVfEUXNQ MUPJR|UxRTRwMUW0JO69VQ>? NHTh[ZEzPDN2Mkm0PC=>
SKW-3/KE-37 NV3F[XF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYexNEDPxE1? MWi0PEBp NVrBWVg6TE2VTx?= MYXJR|UxRTBwN{GyJO69VQ>? MWKyOFM1Ojl2OB?=
SUPT-11 M3vhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGxNEDPxE1? NVKxN|l3PDhiaB?= M4DpNWROW09? NGDpPG1KSzVyPUSuOFc{KM7:TR?= NHi1fGQzPDN2Mkm0PC=>
JURKAT M2HOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zNWVExKM7:TR?= MWi0PEBp MoHnSG1UVw>? NEjZVYFKSzVyPUSuPFk{KM7:TR?= M2r3TVI1OzR{OUS4
CCRF-CEM NUG5fWhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWxNEDPxE1? NF7seHo1QCCq NEe3UHpFVVOR NXK5R3k{UUN3ME2xMlM3OCEQvF2= MXiyOFM1Ojl2OB?=
LOUCY M4H5XGFxd3C2b4TpZ{BCe3OjeR?= NH:ybVIzKM7:TR?= M330TlQ5KGh? Ml;ISG1UVw>? Mnn3RZBweHSxc3nzJIlv\HWldHnvci=> MVyyOFM1Ojl2OB?=

... Click to View More Cell Line Experimental Data

体内研究 ABT-199 (100 mg/kg)处理RS4;11 移植瘤,产生的最大肿瘤生长抑制率为95%,肿瘤生长延迟152%。ABT-199单独处理或与SDX-105及其他药剂联用处理DoHH2和Granta-519移植瘤,也抑制肿瘤生长。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

亲和力分析:

竞争性荧光偏振检测测定ABT-199对Bcl-2家族的不同亚型的亲和力(Ki 或 IC50)。使用如下肽探针/蛋白对:f-bad (1 nM) 与Bcl-xL (6 nM), f-Bax (1 nM) 与 Bcl-2 (10 nM),f-Bax(1 nM) 与Bcl-w (40 nM), f-Noxa(2 nM) 与Mcl-1 (40 nM), 及 f-Bax (1 nM)与Bcl-2-A1(15 nM)。使用时间分辨荧光共振能量转移检测测定对Bcl-xL的亲和力。Bcl-xL (1 nM, His标记的 ) 与200 nM f-Bak, 1 nM Tb标记的anti-His抗体, 及 ABT-199,在室温下混合30分钟。在Envision酶标仪上,使用340/35 nm 激发滤光片及520/525 (f-Bak) 和495/510 nm (Tb标记的anti-His抗体) 发射滤光片,测量荧光值。
细胞实验:[1]
+ 展开
  • Cell lines: NHL, DLBCL, MCL, AML 和 ALL 细胞系
  • Concentrations: ~1 μM
  • Incubation Time: 48 小时
  • Method: RS4;11 细胞按每孔5×104个接种在96孔板中,使用初始1 μM-0.05 nM。在半对数期稀释的ABT-199 处理细胞。白血病和淋巴瘤细胞系按每孔1.5-2×104个接种在合适的培养基中,与ABT-199温育48小时。使用Cell TiterGlo 试剂测定对细胞增殖的影响。通过对浓度-反应数据非线性回归分析测定EC50值。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 雌性 C.B-17 SCID 小鼠(携带DoHH2 和Granta-519 移植瘤) 和雌性 C.B-17 SCID-beige 小鼠 (携带RS4;11和 Toledo 移植瘤)
  • Formulation: 60% Phosal 50丙二醇(PG), 30%聚乙二醇(PEG) 400 和 10% 乙醇
  • Dosages: ~100 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL warmed (115.14 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+50% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 868.44
化学式

C45H50ClN7O7S

CAS号 1257044-40-8
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03583424 Recruiting Hematopoietic Cell Transplantation Recipient|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Transformed Indolent Non-Hodgkin Lymphoma Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) July 9 2018 Phase 1|Phase 2
NCT03379051 Recruiting Chronic Lymphocytic Leukemia TG Therapeutics Inc.|James P. Wilmot Cancer Center April 9 2018 Phase 1|Phase 2
NCT03415035 Recruiting Chronic Lymphocytic Leukemia (CLL) AbbVie March 9 2018 --
NCT03223610 Recruiting Lymphoma|Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Burkitt Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 9 2018 Phase 1
NCT03236857 Recruiting Malignancies|Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Non-Hodgkin''s Lymphoma|Neuroblastoma AbbVie|Roche-Genentech November 9 2017 Phase 1
NCT02611323 Recruiting Non-Hodgkin''s Lymphoma Hoffmann-La Roche March 9 2016 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Could you please offer some advice on the half-life of the drug ?

  • 回答:

    According to the reference (https://www.ncbi.nlm.nih.gov/pubmed/24212376), the half-life of ABT-199 in dogs is 12.9 hr.

  • 问题 2:

    how to prepare the working solution for mice including how to dissolve the powder?

  • 回答:

    We recommend the following vehicle for ABT 199, 30% PEG400/0.5% Tween80/5% Propylene glycol (64.5% water, V/V), at a concentration up to 20mg/ml. Its a homogeneous suspension and can be used for oral gavage.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

相关Bcl-2产品

Tags: 购买Venetoclax (ABT-199, GDC-0199) | Venetoclax (ABT-199, GDC-0199)供应商 | 采购Venetoclax (ABT-199, GDC-0199) | Venetoclax (ABT-199, GDC-0199)价格 | Venetoclax (ABT-199, GDC-0199)生产 | 订购Venetoclax (ABT-199, GDC-0199) | Venetoclax (ABT-199, GDC-0199)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID